• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

滤泡性淋巴瘤患者接受CD3/CD20双特异性抗体治疗后发生播散性复杂感染

Disseminated Complex Infection Following CD3/CD20 Bispecific Antibody Therapy in a Patient With Follicular Lymphoma.

作者信息

Little Jessica S, Hurtado Rocio M, Boire Nicholas, Baden Lindsey R, Laga Alvaro C, Silk Ann W, Jacobson Caron A

机构信息

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Open Forum Infect Dis. 2024 Aug 8;11(9):ofae460. doi: 10.1093/ofid/ofae460. eCollection 2024 Sep.

DOI:10.1093/ofid/ofae460
PMID:39224237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11368541/
Abstract

Infections remain a major concern following bispecific antibody therapy but are not well described in pivotal trials. We present the first well-documented case of a classic but rare opportunistic infection, disseminated complex, in a patient receiving bispecific antibody therapy.

摘要

感染仍然是双特异性抗体治疗后的一个主要问题，但在关键试验中并未得到充分描述。我们报告了首例记录详尽的经典但罕见的机会性感染——播散性隐球菌病，该病例发生在一名接受双特异性抗体治疗的患者身上。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b30/11368541/e72cfca295d9/ofae460f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b30/11368541/e72cfca295d9/ofae460f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b30/11368541/e72cfca295d9/ofae460f2.jpg

相似文献

1
Disseminated Complex Infection Following CD3/CD20 Bispecific Antibody Therapy in a Patient With Follicular Lymphoma.滤泡性淋巴瘤患者接受CD3/CD20双特异性抗体治疗后发生播散性复杂感染
Open Forum Infect Dis. 2024 Aug 8;11(9):ofae460. doi: 10.1093/ofid/ofae460. eCollection 2024 Sep.
2
Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report.抗反转录病毒治疗患者发生播散性鸟分枝杆菌复合体感染致蛋白丢失性肠病：尸检病例报告。
AIDS Res Ther. 2021 Nov 29;18(1):90. doi: 10.1186/s12981-021-00417-0.
3
Cerebral mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation of therapy for disseminated mycobacterium avium complex infection.一名感染人类免疫缺陷病毒（HIV）的患者在免疫重建及播散性鸟分枝杆菌复合群感染治疗停止后发生脑鸟分枝杆菌感染。
Eur J Clin Microbiol Infect Dis. 2001 Mar;20(3):199-201. doi: 10.1007/pl00011252.
4
Selective expansion of gammadelta T cells among liver-derived lymphocytes of AIDS patients with disseminated Mycobacterium avium complex infection.
Clin Immunol Immunopathol. 1997 Nov;85(2):151-7. doi: 10.1006/clin.1997.4410.
5
Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy.在有效的抗逆转录病毒治疗后成功停用播散性鸟分枝杆菌复合群感染的治疗。
Ann Intern Med. 2002 Nov 5;137(9):734-7. doi: 10.7326/0003-4819-137-9-200211050-00008.
6
complex and co-infection in a patient with acquired immunodeficiency syndrome: a case report.一名获得性免疫缺陷综合征患者的复杂感染与合并感染：病例报告
Acta Clin Belg. 2022 Jun;77(3):679-684. doi: 10.1080/17843286.2021.1919845. Epub 2021 Apr 22.
7
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
8
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.CD20×CD3 双特异性抗体治疗淋巴瘤：2023 年美国临床肿瘤学会年会最新进展。
J Hematol Oncol. 2023 Aug 3;16(1):90. doi: 10.1186/s13045-023-01488-4.
9
Gammadelta T cells increase with Mycobacterium avium complex infection but not with tuberculosis in AIDS patients.在艾滋病患者中，γδ T细胞在鸟分枝杆菌复合群感染时会增加，但在结核病感染时不会增加。
Int Immunol. 1999 Sep;11(9):1475-8. doi: 10.1093/intimm/11.9.1475.
10
Incidence of disseminated Mycobacterium avium-complex infection in HIV patients receiving antiretroviral therapy with use of Mycobacterium avium-complex prophylaxis.接受抗逆转录病毒治疗并采用鸟分枝杆菌复合群预防措施的HIV患者中播散性鸟分枝杆菌复合群感染的发生率
Int J STD AIDS. 2017 Dec;28(14):1426-1432. doi: 10.1177/0956462417713432. Epub 2017 Jun 7.

引用本文的文献

1
Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma.多发性骨髓瘤患者使用替雷利珠单抗后发生的非结核分枝杆菌感染
Haematologica. 2025 Jun 1;110(6):1436-1442. doi: 10.3324/haematol.2024.286675. Epub 2025 Feb 6.

本文引用的文献

1
Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis.接受双特异性抗体治疗的淋巴瘤患者的感染：一项系统评价和荟萃分析。
Blood Adv. 2024 Jul 9;8(13):3555-3559. doi: 10.1182/bloodadvances.2024012916.
2
The present and future of bispecific antibodies for cancer therapy.双特异性抗体在癌症治疗中的现在和未来。
Nat Rev Drug Discov. 2024 Apr;23(4):301-319. doi: 10.1038/s41573-024-00896-6. Epub 2024 Mar 6.
3
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.
双特异性抗体治疗多发性骨髓瘤患者的感染特征和发生率：一项全国性回顾性研究。
Clin Microbiol Infect. 2024 Jun;30(6):764-771. doi: 10.1016/j.cmi.2024.02.023. Epub 2024 Mar 1.
4
Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients.免疫功能低下患者感染事件报告标准化推进的共识立场声明
Lancet Infect Dis. 2024 Jan;24(1):e59-e68. doi: 10.1016/S1473-3099(23)00377-8. Epub 2023 Sep 6.
5
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.接受双特异性抗体治疗的 MM 患者的感染监测、预防和治疗：专家小组的共识建议。
Blood Cancer J. 2023 Aug 1;13(1):116. doi: 10.1038/s41408-023-00879-7.
6
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.多发性骨髓瘤中双特异性抗体相关感染：系统评价和荟萃分析。
Blood Adv. 2023 Oct 10;7(19):5898-5903. doi: 10.1182/bloodadvances.2023010539.
7
Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma.认识到双特异性抗体治疗多发性骨髓瘤试验中的感染风险。
J Clin Oncol. 2023 Apr 1;41(10):1949-1951. doi: 10.1200/JCO.22.02197. Epub 2023 Jan 30.
8
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.连续双特异性分子暴露诱导的 T 细胞耗竭可通过无治疗间隔得到改善。
Blood. 2022 Sep 8;140(10):1104-1118. doi: 10.1182/blood.2022015956.
9
Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma.多发性骨髓瘤中B细胞成熟抗原导向免疫疗法的感染风险。
Blood Adv. 2022 Apr 26;6(8):2466-2470. doi: 10.1182/bloodadvances.2021006178.
10
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap.双特异性抗体治疗及其在感染方面的应用和风险：弥合知识差距。
Blood Rev. 2021 Sep;49:100810. doi: 10.1016/j.blre.2021.100810. Epub 2021 Feb 27.